vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Whitestone REIT (WSR). Click either name above to swap in a different company.

AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $43.9M, roughly 1.0× Whitestone REIT). Whitestone REIT runs the higher net margin — 52.0% vs -19.9%, a 71.9% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 7.5%). Whitestone REIT produced more free cash flow last quarter ($50.5M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 8.7%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Whitestone REIT is a publicly traded real estate investment trust that acquires, owns, manages and redevelops open-air community shopping centers, primarily located in high-growth metropolitan areas across the southwestern and southeastern United States. Its property portfolio is largely anchored by daily necessity, service-focused retail tenants that cater to regular local consumer demand.

ABCL vs WSR — Head-to-Head

Bigger by revenue
ABCL
ABCL
1.0× larger
ABCL
$44.9M
$43.9M
WSR
Growing faster (revenue YoY)
ABCL
ABCL
+780.8% gap
ABCL
788.4%
7.5%
WSR
Higher net margin
WSR
WSR
71.9% more per $
WSR
52.0%
-19.9%
ABCL
More free cash flow
WSR
WSR
$95.1M more FCF
WSR
$50.5M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
8.7%
WSR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
WSR
WSR
Revenue
$44.9M
$43.9M
Net Profit
$-8.9M
$22.8M
Gross Margin
Operating Margin
-63.7%
53.0%
Net Margin
-19.9%
52.0%
Revenue YoY
788.4%
7.5%
Net Profit YoY
73.9%
31.7%
EPS (diluted)
$-0.03
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
WSR
WSR
Q4 25
$44.9M
$43.9M
Q3 25
$9.0M
$41.0M
Q2 25
$17.1M
$37.9M
Q1 25
$4.2M
$38.0M
Q4 24
$5.0M
$40.8M
Q3 24
$6.5M
$38.6M
Q2 24
$7.3M
$37.6M
Q1 24
$10.0M
$37.2M
Net Profit
ABCL
ABCL
WSR
WSR
Q4 25
$-8.9M
$22.8M
Q3 25
$-57.1M
$18.3M
Q2 25
$-34.7M
$5.1M
Q1 25
$-45.6M
$3.7M
Q4 24
$17.3M
Q3 24
$-51.1M
$7.6M
Q2 24
$-36.9M
$2.6M
Q1 24
$-40.6M
$9.3M
Operating Margin
ABCL
ABCL
WSR
WSR
Q4 25
-63.7%
53.0%
Q3 25
-851.8%
45.5%
Q2 25
-290.2%
13.8%
Q1 25
-1479.6%
10.2%
Q4 24
43.3%
Q3 24
-1439.4%
20.3%
Q2 24
-1276.2%
7.2%
Q1 24
-551.5%
25.9%
Net Margin
ABCL
ABCL
WSR
WSR
Q4 25
-19.9%
52.0%
Q3 25
-637.8%
44.7%
Q2 25
-203.3%
13.3%
Q1 25
-1077.2%
9.7%
Q4 24
42.5%
Q3 24
-785.4%
19.7%
Q2 24
-504.3%
6.9%
Q1 24
-408.0%
25.1%
EPS (diluted)
ABCL
ABCL
WSR
WSR
Q4 25
$-0.03
$0.43
Q3 25
$-0.19
$0.35
Q2 25
$-0.12
$0.10
Q1 25
$-0.15
$0.07
Q4 24
$0.34
Q3 24
$-0.17
$0.15
Q2 24
$-0.13
$0.05
Q1 24
$-0.14
$0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
WSR
WSR
Cash + ST InvestmentsLiquidity on hand
$128.5M
$4.9M
Total DebtLower is stronger
$649.4M
Stockholders' EquityBook value
$966.9M
$458.1M
Total Assets
$1.4B
$1.2B
Debt / EquityLower = less leverage
1.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
WSR
WSR
Q4 25
$128.5M
$4.9M
Q3 25
$83.2M
$6.8M
Q2 25
$92.4M
$5.3M
Q1 25
$159.3M
$5.6M
Q4 24
$156.3M
$5.2M
Q3 24
$126.6M
$2.5M
Q2 24
$148.3M
$3.2M
Q1 24
$123.6M
$6.2M
Total Debt
ABCL
ABCL
WSR
WSR
Q4 25
$649.4M
Q3 25
Q2 25
Q1 25
Q4 24
$632.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABCL
ABCL
WSR
WSR
Q4 25
$966.9M
$458.1M
Q3 25
$964.0M
$439.5M
Q2 25
$1.0B
$427.5M
Q1 25
$1.0B
$431.0M
Q4 24
$1.1B
$438.2M
Q3 24
$1.1B
$419.5M
Q2 24
$1.1B
$418.3M
Q1 24
$1.1B
$421.6M
Total Assets
ABCL
ABCL
WSR
WSR
Q4 25
$1.4B
$1.2B
Q3 25
$1.4B
$1.1B
Q2 25
$1.4B
$1.2B
Q1 25
$1.3B
$1.1B
Q4 24
$1.4B
$1.1B
Q3 24
$1.4B
$1.1B
Q2 24
$1.4B
$1.1B
Q1 24
$1.5B
$1.1B
Debt / Equity
ABCL
ABCL
WSR
WSR
Q4 25
1.42×
Q3 25
Q2 25
Q1 25
Q4 24
1.44×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
WSR
WSR
Operating Cash FlowLast quarter
$-34.7M
$50.8M
Free Cash FlowOCF − Capex
$-44.6M
$50.5M
FCF MarginFCF / Revenue
-99.4%
114.9%
Capex IntensityCapex / Revenue
21.9%
0.7%
Cash ConversionOCF / Net Profit
2.22×
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
WSR
WSR
Q4 25
$-34.7M
$50.8M
Q3 25
$-52.6M
$18.0M
Q2 25
$-32.4M
$13.8M
Q1 25
$-11.6M
$3.1M
Q4 24
$-108.6M
$58.2M
Q3 24
$-28.9M
$16.4M
Q2 24
$-30.0M
$12.3M
Q1 24
$-41.7M
$11.5M
Free Cash Flow
ABCL
ABCL
WSR
WSR
Q4 25
$-44.6M
$50.5M
Q3 25
$-61.5M
Q2 25
$-45.8M
Q1 25
$-22.2M
Q4 24
$-187.0M
$58.0M
Q3 24
$-47.4M
Q2 24
$-50.1M
Q1 24
$-65.8M
FCF Margin
ABCL
ABCL
WSR
WSR
Q4 25
-99.4%
114.9%
Q3 25
-687.0%
Q2 25
-267.9%
Q1 25
-524.0%
Q4 24
-3702.8%
142.1%
Q3 24
-728.4%
Q2 24
-683.8%
Q1 24
-661.5%
Capex Intensity
ABCL
ABCL
WSR
WSR
Q4 25
21.9%
0.7%
Q3 25
99.7%
Q2 25
78.2%
Q1 25
251.1%
Q4 24
1552.7%
0.5%
Q3 24
284.6%
Q2 24
274.6%
Q1 24
242.5%
Cash Conversion
ABCL
ABCL
WSR
WSR
Q4 25
2.22×
Q3 25
0.98×
Q2 25
2.74×
Q1 25
0.83×
Q4 24
3.36×
Q3 24
2.15×
Q2 24
4.73×
Q1 24
1.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons